Studies have shown that patients with NSCLC who overexpress PD-L1 tend to respond more favorably to immunotherapy and demonstrate higher survival rates compared to those whose tumors do not express or have low expression of PD-L1. The gene discussed is CD274; the disease is non-small cell lung carcinoma.